Apotea AB

Total Valuation

Apotea AB carries a market capitalization of 8.07B, placing it among publicly traded companies globally. Its enterprise value stands at 9.43B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Share Statistics

Apotea AB currently has 104.07M shares outstanding.

Valuation Ratios

Apotea AB trades at a trailing price-to-earnings ratio of 36.72. The price-to-sales ratio is 1.32, and the price-to-book ratio stands at 12.26.

Enterprise Valuation

On an enterprise value basis, Apotea AB trades at an EV/EBITDA multiple of 30.05 and an EV/FCF ratio of 15.89. The EV/Sales ratio of 1.36 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 30.05 provides insight into valuation relative to core operating earnings.

Financial Position

Apotea AB maintains a current ratio of 1.18, meaning it holds 1.2x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 42.65, indicating elevated leverage, while an interest coverage ratio of 36.93 demonstrates strong ability to service its debt obligations.

Financial Efficiency

Apotea AB posts a return on equity of 180.55 and a return on invested capital of 111.99.

Taxes

Over the trailing twelve months, Apotea AB has paid 60.90M in income taxes, reflecting an effective tax rate of 19.73.

Stock Price Statistics

Apotea AB's stock has declined approximately -11.63056% over the past 52 weeks. The 50-day moving average sits at 75.04, while the 200-day moving average is 75.96.

Income Statement

Over the trailing twelve months, Apotea AB generated 6.94B in revenue and converted that into 249.20M in net income, yielding earnings per share of 2.39. EBITDA reached 313.90M, while operating income came in at 313.90M.

Balance Sheet

Apotea AB holds 69.20M in cash and equivalents against 331.90M in total debt, resulting in a net debt position of -69.00M. Total book value stands at 746.40M, with working capital of 171.00M providing operational flexibility.

Cash Flow

Apotea AB produced 371.90M in operating cash flow over the past twelve months. After subtracting -215.00M in capital expenditures, free cash flow totaled 156.90M - equivalent to 1.51 per share.

Margins

Apotea AB operates with a gross margin of 27.50, reflecting its pricing power and cost economics. The operating margin of 4.52 and net profit margin of 3.59 provide insight into operational efficiency.

Dividends & Yields

Scores

Apotea AB posts an Altman Z-Score of 9.37, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.